Navigation Links
Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
Date:7/7/2010

s the issues raised in the current FDA letter as well as the process for moving forward.

Based upon the in-person meeting with the FDA reviewers, the company will determine the appropriate course of action, which could include filing a new 510(k) application or filing an appeal related to the current application.

Nephros has engaged King & Spalding LLP as regulatory counsel to advise the company in its next interactions with the FDA.  The company also intends to utilize the FDA's Ombudsman process.

Impact on Operations

The current decision by the U.S. FDA with regard to Nephros's HDF system does not impact the ability of the company to market and sell its mid-dilution (MD) filters for hemodiafiltration procedures outside of the U.S.

The Nephros dual stage ultrafilter (DSU) received 510(k) marketing clearance from the FDA in 2009 to be used to filter biological contaminants from water and bicarbonate concentrate used in hemodialysis procedures.  The 510(k) approval for the DSU filters is unrelated to the 510(k) application for the company's HDF system.

Nephros continues to work with STERIS Corporation under the development agreement executed in March 2010.

Nephros is continuing the development of its dual stage ultra reliable personal water filtration system under support from its U.S. Department of Defense appropriation.

About Nephros, Inc.

Nephros, Inc., headquartered in River Edge, New Jersey, is a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification.

The Nephros hemodiafiltr
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
2. Nephros Reports 2010 First Quarter Financial Results
3. Nephros Signs Development Agreement with STERIS
4. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
5. Nephros Reports 2009 Third Quarter Financial Results
6. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
7. Watsons Generic Prograf® 5 mg Receives FDA Approval
8. Renhuang Pharmaceuticals Receives Approval to List on the NYSE Amex
9. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
10. Biomerix Ventral Hernia Repair Mesh Receives FDA 510(k) Clearance
11. AMS Receives 510(k) Clearance of Its Revolutionary MoXy(TM) Liquid Cooled Fiber for Fast, Safe Treatment of Enlarged Prostate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... MENLO PARK, Calif. , May 29, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, presented additional ... Cancer Research (AACR) Advances in Brain Cancer Research ... product candidate VAL-083 (dianhydrogalactitol) to treat ...
(Date:5/29/2015)... -- World-renowned prostate surgeon and New York Urologist, Dr. David ... MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive prostate cancer ... at Lenox Hill Hospital is the only center using the ... York City . We,ve seen tremendous improvement in detecting ... of an MRI makes for a much more accurate diagnosis, ...
(Date:5/28/2015)... HOUSTON , May 28, 2015 /PRNewswire/ - ESSA Pharma ... results for the second quarter and three and six months ... in Canadian dollars and in accordance with International Financial Reporting ... ESSA recorded a net loss of $5.9 million ($0.35 per ... (Q2-2015), compared to a net loss of $0.4 million ($0.03 ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... 9 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... with eight presentations (including three oral talks and two ... Scientific Sessions in New Orleans by Isis and its ... ISIS-SGLT2Rx showing a robust and sustained reduction in sodium ...
... for America,s Health (TFAH) and the Robert Wood Johnson ... which finds that Americans rank prevention as the most ... funding for prevention programs to reduce disease and keep ... conducted by Greenberg Quinlan Rosner Research and Public Opinion ...
Cached Medicine Technology:Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 2Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 3Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 4Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 5Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 6New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 2New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 3New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 4New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 5
(Date:5/29/2015)... Dot Hill can mark one more item off her bucket list: ... retirement community is the oldest woman to have flown at ... great fun!”, she exclaimed. “I’ve always wanted to jump from ... thought this would be ok.” , “We put on nylon coveralls, ... described. “I don’t remember it being noisy, but the wind ...
(Date:5/29/2015)... Los Angeles, CA (PRWEB) May 29, 2015 ... Old Should You Really be When You Get Botox ... anti-aging questions according to Google. Elle partnered with Google to ... these questions. The most searched question in California, for example, ... South Carolina the most common search query is what's the ...
(Date:5/29/2015)... Jan Wooden Howse lost her husband and ... all else: God does no wrong. , It’s fitting, then, ... passing is titled “God Does No Wrong.” It focuses on ... personal tragedy. , “My story has a positive message ... into something productive, something healing,” Howse said. , “God Does ...
(Date:5/29/2015)... 29, 2015 Johnson & Johnson ... confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement with ... to his use of the antipsychotic medication. According ... for the third bellwether trial to involve male ... underway in Pennsylvania’s Philadelphia Court of Common Pleas, ...
(Date:5/29/2015)... Diego, California (PRWEB) May 29, 2015 A ... Core” and have joined the national effort to teach this ... parents in the U.S. have been “sickened” by the recent ... However, love it or hate it, Common Core is now ... District of Columbia. Parents are now seeking ways to ...
Breaking Medicine News(10 mins):Health News:Indoor Skydiving Brings Thrills to Seniors 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:Turning grief from a child’s passing into virtue 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Doctors Discover a Cure for the Common Core 2
... FASgen is pleased to report the,publication of ... one of the Company,s proprietary compounds. In a ... supported,research into the selective inhibition of fatty acid ... potential therapeutic agent against various,forms of solid tumor ...
... KAYSVILLE, Utah, Dec. 28 A Utah company wants ... Virtual Trainer Pro.,MediaRif,s online software takes the complexity out ... Strength training is on the rise, and not just ... reports that 21.9% of women use,strength training as a ...
... KV,s Securities until February 15, ... ... KV Pharmaceutical Company,(NYSE: KVa/KVb) a fully integrated specialty pharmaceutical company ... products,announced today that NYSE Regulation, Inc. has granted KV,s request for ...
... 28 Caraco Pharmaceutical,Laboratories, Ltd., (Amex: CPD ) ... has granted final approval for the Company,s,Abbreviated New Drug ... 5 mg and 10 mg, (Cetirizine HCl)., Cetirizine ... products in,two strengths of 5 mg and 10 mg, ...
... Therapeutics Inc.,("Transition" or the "Company") (TSX: TTH; NASDAQ: ... has been appointed Vice President of,Business Development. Since ... key member of the Company,s management team and ... a broad range of activities,including licensing and intellectual ...
... that contact with some commonly used pesticides in farm work ... women are an understudied occupational group, said Jane Hoppin, Sc.D., ... author of the study. More than half the women in ... about the risks. , The study was published in the ...
Cached Medicine News:Health News:Personal Fitness Training Goes Online for 2008 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R) 2Health News:Transition Therapeutics Announces Appointment of Vice-President of Business Development 2Health News:Handling pesticides associated with greater asthma risk in farm women 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: